Next generation sequencing in MPNs. Lessons from the past and prospects for use as predictors of prognosis and treatment responses
V Skov - Cancers, 2020 - mdpi.com
The myeloproliferative neoplasms (MPNs) are acquired hematological stem cell neoplasms
characterized by driver mutations in JAK2, CALR, or MPL. Additive mutations may appear in …
characterized by driver mutations in JAK2, CALR, or MPL. Additive mutations may appear in …
JAK2 Variant Signaling: Genetic, Hematologic and Immune Implication in Chronic Myeloproliferative Neoplasms
DG Torres, J Paes, AG da Costa, A Malheiro, GV Silva… - Biomolecules, 2022 - mdpi.com
The JAK2 V617F variant constitutes a genetic alteration of higher frequency in BCR/ABL1
negative chronic myeloproliferative neoplasms, which is caused by a substitution of a G˃ T …
negative chronic myeloproliferative neoplasms, which is caused by a substitution of a G˃ T …
LSD1 inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone
JS Jutzi, M Kleppe, J Dias, HF Staehle, K Shank… - …, 2018 - journals.lww.com
Despite recent advances, the myeloproliferative neoplasms (MPNs) are attended by
considerable morbidity and mortality. Janus kinase (Jak) inhibitors such as ruxolitinib …
considerable morbidity and mortality. Janus kinase (Jak) inhibitors such as ruxolitinib …
Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era
L Falchi, HM Kantarjian, S Verstovsek - Leukemia, 2017 - nature.com
The molecular characterization of myeloproliferative neoplasms, including essential
thrombocythemia (ET), has enabled deeper understanding of their pathogenesis. A driver …
thrombocythemia (ET), has enabled deeper understanding of their pathogenesis. A driver …
Prognostic value of ASXL1 mutations in patients with primary myelofibrosis and its relationship with clinical features: a meta-analysis
Z Wang, W Liu, M Wang, Y Li, X Wang, E Yang… - Annals of …, 2021 - Springer
Additional sex combs like 1 (ASXL1) mutations are one of the most common molecular
biological abnormalities in patients with primary myelofibrosis (PMF), and the effect of these …
biological abnormalities in patients with primary myelofibrosis (PMF), and the effect of these …
Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
L Yang, X Wei, Y Gong - Cancer Medicine, 2024 - Wiley Online Library
Objective The objective of the study was to determine the prognosis and risk factors for
additional sex combs like 1 (ASXL1) mutations in patients with acute myeloid leukemia …
additional sex combs like 1 (ASXL1) mutations in patients with acute myeloid leukemia …
[HTML][HTML] Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome
J Asp, B Andréasson, U Hansson, C Wasslavik… - …, 2016 - ncbi.nlm.nih.gov
Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical
outcome - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
outcome - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage …
Somatic mutations in Philadelphia chromosome-negative myeloproliferative neoplasms
SF Cristina, B Polo, JF Lacerda - Seminars in hematology, 2018 - Elsevier
Myeloproliferative neoplasms (MPN) include polycythemia vera (PV), essential
thrombocythemia (ET), and primary myelofibrosis (PMF). MPN are characterized by clonal …
thrombocythemia (ET), and primary myelofibrosis (PMF). MPN are characterized by clonal …
Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato …
E Shumilov, J Flach, T Pabst, M Fiedler… - Critical reviews in …, 2018 - Elsevier
Owing to the introduction of next-generation sequencing (NGS) new challenges for
diagnostic algorithms and the interpretation of the results for therapeutic decision making in …
diagnostic algorithms and the interpretation of the results for therapeutic decision making in …
[HTML][HTML] Essential thrombocythemia among patients with myeloproliferative neoplasms in haematology unit of a Tertiary Care Centre: a descriptive cross-sectional …
SK Sah, S Shah, SB Tiwari, BS Paudel… - JNMA: Journal of the …, 2022 - ncbi.nlm.nih.gov
Methods: This was a descriptive cross-sectional study at a tertiary care centre from
September, 2020 to September, 2021 (Reference number: 48 (6-11) E2077/076). All the …
September, 2020 to September, 2021 (Reference number: 48 (6-11) E2077/076). All the …